Endothelin Blockade in Patients With Single Ventricle Physiology

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Congenital Heart Disease
Interventions
DRUG

Bosentan

Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.

Trial Locations (1)

90095

UCLA Medical Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Actelion

INDUSTRY

lead

University of California, Los Angeles

OTHER